Annual report pursuant to Section 13 and 15(d)

Condensed Consolidated Statements of Operations

v3.3.1.900
Condensed Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Revenue:    
Contract research revenue $ 194,494 $ 0
Costs and Expenses:    
Research and development 5,292,193 5,175,520
General and administrative 4,813,800 5,289,479
Total costs and expenses 10,105,993 10,464,999
Loss from operations (9,911,499) (10,464,999)
Sale of New Jersey net operating loss 756,472 269,127
Other income/(expense), net 19,627 (25,173)
Net loss $ (9,135,400) $ (10,221,045)
Net loss per share - basic and diluted (in dollars per share) $ (0.18) $ (0.32)
Weighted average common shares outstanding:    
Basic and diluted (in shares) 51,481,002 32,076,717